These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

890 related articles for article (PubMed ID: 12529666)

  • 41. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter.
    Tabe Y; Konopleva M; Kondo Y; Contractor R; Jin L; Ruvolo V; Tsutsumi-Ishii Y; Miyake K; Miyake N; Ohsaka A; Nagaoka I; Issa JP; Andreeff M
    Ann Hematol; 2006 Oct; 85(10):689-704. PubMed ID: 16832676
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interferon augments PML and PML/RAR alpha expression in normal myeloid and acute promyelocytic cells and cooperates with all-trans retinoic acid to induce maturation of a retinoid-resistant promyelocytic cell line.
    Nason-Burchenal K; Gandini D; Botto M; Allopenna J; Seale JR; Cross NC; Goldman JM; Dmitrovsky E; Pandolfi PP
    Blood; 1996 Nov; 88(10):3926-36. PubMed ID: 8916959
    [TBL] [Abstract][Full Text] [Related]  

  • 43. WEB-2086 and WEB-2170 trigger apoptosis in both ATRA-sensitive and -resistant promyelocytic leukemia cells and greatly enhance ATRA differentiation potential.
    Laurenzana A; Cellai C; Vannucchi AM; Pancrazzi A; Romanelli MN; Paoletti F
    Leukemia; 2005 Mar; 19(3):390-5. PubMed ID: 15674364
    [TBL] [Abstract][Full Text] [Related]  

  • 44. RARα2 and PML-RAR similarities in the control of basal and retinoic acid induced myeloid maturation of acute myeloid leukemia cells.
    Gianni M; Fratelli M; Bolis M; Kurosaki M; Zanetti A; Paroni G; Rambaldi A; Borleri G; Rochette-Egly C; Terao M; Garattini E
    Oncotarget; 2017 Jun; 8(23):37041-37060. PubMed ID: 27419624
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
    Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A
    Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting of PML/RARalpha is lethal to retinoic acid-resistant promyelocytic leukemia cells.
    Nason-Burchenal K; Allopenna J; Bègue A; Stéhelin D; Dmitrovsky E; Martin P
    Blood; 1998 Sep; 92(5):1758-67. PubMed ID: 9716606
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation.
    Shao W; Benedetti L; Lamph WW; Nervi C; Miller WH
    Blood; 1997 Jun; 89(12):4282-9. PubMed ID: 9192750
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.
    Riccioni R; Pasquini L; Mariani G; Saulle E; Rossini A; Diverio D; Pelosi E; Vitale A; Chierichini A; Cedrone M; Foà R; Lo Coco F; Peschle C; Testa U
    Haematologica; 2005 May; 90(5):612-24. PubMed ID: 15921376
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential changes of retinoid-X-receptor (RXR alpha) and its RAR alpha and PML-RAR alpha partners induced by retinoic acid and cAMP distinguish maturation sensitive and resistant t(15;17) promyelocytic leukemia NB4 cells.
    Duprez E; Lillehaug JR; Gaub MP; Lanotte M
    Oncogene; 1996 Jun; 12(11):2443-50. PubMed ID: 8649786
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A network including PU.1, Vav1 and miR-142-3p sustains ATRA-induced differentiation of acute promyelocytic leukemia cells - a short report.
    Grassilli S; Nika E; Lambertini E; Brugnoli F; Piva R; Capitani S; Bertagnolo V
    Cell Oncol (Dordr); 2016 Oct; 39(5):483-489. PubMed ID: 27480083
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of the retinoid binding properties of the major fusion products present in acute promyelocytic leukemia cells.
    Benedetti L; Levin AA; Scicchitano BM; Grignani F; Allenby G; Diverio D; Lo Coco F; Avvisati G; Ruthardt M; Adamo S; Pelicci PG; Nervi C
    Blood; 1997 Aug; 90(3):1175-85. PubMed ID: 9242550
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint.
    Biondi A; Luciano A; Bassan R; Mininni D; Specchia G; Lanzi E; Castagna S; Cantù-Rajnoldi A; Liso V; Masera G
    Leukemia; 1995 Sep; 9(9):1461-6. PubMed ID: 7658712
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF/RAR alpha patient.
    Guidez F; Huang W; Tong JH; Dubois C; Balitrand N; Waxman S; Michaux JL; Martiat P; Degos L; Chen Z
    Leukemia; 1994 Feb; 8(2):312-7. PubMed ID: 8309256
    [TBL] [Abstract][Full Text] [Related]  

  • 54. All-trans retinoic acid potentiates megakaryocyte colony formation: in vitro and in vivo effects after administration to acute promyelocytic leukemia patients.
    Visani G; Zauli G; Tosi P; Ottaviani E; Gibellini D; Manfroi S; Celeghini C; Pagliarini C; Bassini A; Tura S
    Leukemia; 1994 Dec; 8(12):2183-7. PubMed ID: 7528859
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha.
    Rego EM; Ruggero D; Tribioli C; Cattoretti G; Kogan S; Redner RL; Pandolfi PP
    Oncogene; 2006 Mar; 25(13):1974-9. PubMed ID: 16331271
    [TBL] [Abstract][Full Text] [Related]  

  • 56. UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia.
    Kitareewan S; Pitha-Rowe I; Sekula D; Lowrey CH; Nemeth MJ; Golub TR; Freemantle SJ; Dmitrovsky E
    Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3806-11. PubMed ID: 11891284
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The acute promyelocytic leukemia-specific PML/RAR alpha fusion protein reduces the frequency of commitment to apoptosis upon growth factor deprivation of GM-CSF-dependent myeloid cells.
    Rogaia D; Grignani F; Grignani F; Nicoletti I; Pelicci PG
    Leukemia; 1995 Sep; 9(9):1467-72. PubMed ID: 7658713
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.
    Yoshida H; Kitamura K; Tanaka K; Omura S; Miyazaki T; Hachiya T; Ohno R; Naoe T
    Cancer Res; 1996 Jul; 56(13):2945-8. PubMed ID: 8674046
    [TBL] [Abstract][Full Text] [Related]  

  • 59. cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha.
    Duprez E; Lillehaug JR; Naoe T; Lanotte M
    Oncogene; 1996 Jun; 12(11):2451-9. PubMed ID: 8649787
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. The Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho).
    Fukutani H; Naoe T; Ohno R; Yoshida H; Miyawaki S; Shimazaki C; Miyake T; Nakayama Y; Kobayashi H; Goto S
    Leukemia; 1995 Sep; 9(9):1478-82. PubMed ID: 7658715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.